Health Utilities and Costs for Multiple Sclerosis
Value in Health · 2026-10
DOI: 10.1016/j.jval.2026.08.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-10. Verfasst von Yankier Pijeira Perez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales UK. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Medical Research Council.
Abstract (Originalsprache)
OBJECTIVES: Multiple sclerosis (MS) is a chronic neurologic condition that imposes a significant burden on patients and healthcare systems. We estimated health utilities and the costs of MS within the UK setting. METHODS: Patients with MS recruited to the Trajectories of Outcomes in Neurological Conditions study completed a survey that included the EuroQol EQ-5D-5L, EuroQol visual analog scale and a resource use questionnaire for recording their use of MS-related primary, secondary, and community care services, diagnostic tests, and medicines in the previous 3 months. Data were analyzed descriptively and using regression models. RESULTS: Of the 10 031 patients invited to participate, 5913 (58.9%) returned their survey questionnaires. Overall, participants' mean (95% CI) utility scores were 0.576 (0.568-0.583). These were highest for those with relapsing-remitting MS 0.667 (0.659-0.675) and lowest in secondary progressive MS 0.385 (0.368-0.402). Utility scores ranged from 0.727 (0.720-0.734) for participants with Expanded Disability Status Scale (EDSS) scores 0 ≤ EDSS ≤ 4.0 to 0.125 (0.089-0.162) for those with 8.0 ≤ EDSS ≤ 9.5. In total, 3-month MS-related costs were £2807 (£2665-£2974), ranging from £809 (£563-£1188) for those with 8.0 ≤ EDSS ≤ 9.5 and primary progressive MS to £9390 (£4601-£23 101) for those with 7.0 ≤ EDSS ≤ 7.5 and rapidly evolving MS. Age, sex, MS types, EDSS scores, and some interactions between EDSS band scores and MS types explained the variability in both health utilities and costs. CONCLUSIONS: The impact of MS on health utilities and costs differs by MS type, disability scores, and their interaction. These data can be used in cost-effectiveness analyses to inform healthcare decision making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales UK.
- The Walton NHS Foundation Trust, Liverpool, England UK; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, England, UK.
- Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales UK; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, England, UK. Electronic address: d.…
Förderung
- UKRI Medical Research Council
Zitieren
APA
Pijeira Perez, Y., Young, C. A., Mills, R. J., & Hughes, D. A. (2026). Health Utilities and Costs for Multiple Sclerosis. Value in Health. https://doi.org/10.1016/j.jval.2026.08.015
Vancouver
Pijeira Perez Y, Young CA, Mills RJ, Hughes DA. Health Utilities and Costs for Multiple Sclerosis. Value in Health. 2026. doi:10.1016/j.jval.2026.08.015
BibTeX
@article{PijeiraPerez2026,
author = {Pijeira Perez, Yankier and Young, Carolyn A and Mills, Roger J and Hughes, Dyfrig A},
title = {Health Utilities and Costs for Multiple Sclerosis},
journal = {Value in Health},
year = {2026},
doi = {10.1016/j.jval.2026.08.015}
}
EUVIMED